
    
      The study will include the treatment of participants with mild to moderate AD, and the
      objective is to evaluate the safety and efficacy of two different doses of leuprolide to
      improve the cognitive function and slow the progression of AD, as measured by the ADAS-COG
      and the Clinical Global Impression (CGI). Measures of behavioral disturbances and quality of
      life of the caregiver will be made also. The study design is randomized, double blind,
      placebo-controlled, parallel group design with a 2:1 randomization of drug to placebo. Sample
      size will include 90 participants
    
  